Utrecht, The Netherlands
NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences.
We are further developing this technology for both research and clinical purposes as a method for the delivery of biologicals that is safe, non-toxic, highly efficient, and easy to use.
Our goal is to be a leader in technologies for the transduction of proteins and other bioactive molecules into primary cells.
NTrans Technologies today announced it has been awarded a prestigious, €1.5M EU SME instrument grant. NTrans Technologies is a spin-off company that emerged from research of the Hubrecht Institute. The company is based on a proprietary technology (iTOP), which allows the intracellular delivery of therapeutic proteins in a wide range